OP
SAGE

ORG Partners’s Sage Therapeutics SAGE Stock Holding History

ORG Partners’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5
Closed -$45 – 1666
2025
Q2 		$45 Hold
5
– – ﹤0.01% 1502
2025
Q1 		$39 Hold
5
– – ﹤0.01% 1369
2024
Q4 		$27 Hold
5
– – ﹤0.01% 1272
2024
Q3 		$36 Hold
5
– – ﹤0.01% 1138
2024
Q2 		$55 Buy
+5
New +$64 ﹤0.01% 1765
2024
Q1 		– Sell
-5
Closed -$108 – 974
2023
Q4 		$108 Hold
5
– – ﹤0.01% 1092
2023
Q3 		$102 Hold
5
– – ﹤0.01% 1305
2023
Q2 		$241 Buy
+5
New +$249 ﹤0.01% 1317

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

ORG Partners's SAGE Position: Q3 2025 in Review

ORG Partners sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 5 shares — an estimated $45 sold.

ORG Partners first reported a position in SAGE in Q2 2023 and held it in 8 quarters. The position peaked at $241 in Q2 2023. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • ORG Partners reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • ORG Partners sold 5 Sage Therapeutics shares in Q3 2025, an estimated $45.
  • ORG Partners first reported a position in Sage Therapeutics in Q2 2023 and held it in 8 quarters.
  • ORG Partners's Sage Therapeutics position peaked at $241 in Q2 2023.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on ORG Partners's 13F filing for Q3 2025, filed 24 Oct 2025.